Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 06 December 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Sofosbuvir and ribavirin for Hepatitis C genotype 1

This week's issue of the Journal of the American Medical Association investigates sofosbuvir and ribavirin for Hepatitis C genotype 1 in patients with unfavorable treatment characteristics.

News image

The efficacy of directly acting antiviral agents in interferon-free regimens for the treatment of chronic hepatitis C infections needs to be evaluated in different populations.

Dr Anuoluwapo Osinusi and colleagues from Maryland, USA determined the efficacy and safety of sofosbuvir with weight-based or low-dose ribavirin among a population with unfavorable treatment characteristics.

Single-center, randomized, 2-part, open-label phase 2 study involving 60 treatment-naive patients with hepatitis C virus (HCV) genotype 1 enrolled at the National Institutes of Health.

In the study’s first part, 10 participants with early to moderate liver fibrosis were treated with 400 mg/d of sofosbuvir and weight-based ribavirin for 24 weeks.

The most frequent adverse events included headaches
Journal of the American Medical Association

In the second part, 50 participants with all stages of liver fibrosis were randomized 1:1 to receive 400 mg of sofosbuvir with either weight-based or low-dose 600 mg/d of ribavirin for 24 weeks.

The team's primary study end point was the proportion of participants with undetectable HCV viral load 24 weeks after treatment completion.

In the first part of the study, 9 participants achieved sustained virological response rates.

In the second part, 7 participants in the weight-based group, and 10 in the low-dose group relapsed after treatment completion leading to sustained virological response rates of 68% in the weight-based group, and 48% in the low-dose group.

The team found that 20 individuals that participated in a pharmacokinetic-viral kinetic substudy, demonstrated a slower loss rate of infectious virus in relapsers than in participants who achieved sustained virological response rates.

The researchers observed that the most frequent adverse events were headache, anemia, fatigue, and nausea.

There were 7 grade 3 events including anemia, neutropenia, nausea, hypophosphatemia, and cholelithiasis or pancreatitis.

No one discontinued treatment due to adverse events.

Dr Osinusi's team concludes, "In a population of patients with a high prevalence of unfavorable traditional predictors of treatment response, a 24-week regimen of sofosbuvir and weight-based or low-dose ribavirin resulted in sustained virological response rates of 68% and 48%, respectively."

JAMA 2013; 310(8): 804-811
29 August 2013

Go to top of page Email this page Email this page to a colleague

 06 December 2016 
IBD Disability Index in restorative proctocolectomy
 06 December 2016 
Anti-TNF therapy for IBD
 06 December 2016 
Crohn's disease and thyroid cancer risk
 05 December 2016 
Disease mangement in IBD
 05 December 2016 
New biomarkers for IBD diagnosis
 05 December 2016 
Reducing hospitalization in IBD
 02 December 2016 
Hep E in acute liver failure
 02 December 2016 
Occurrence and severity of alcoholic hepatitis
 02 December 2016 
Food antigen in active eosinophilic esophagitis
 01 December 2016 
Iron deficiency in anemic ulcerative colitis patients
 01 December 2016 
Prognostic factors after paracetamol-induced liver failure
 01 December 2016 
Factors that influence colorectal cancer screening findings
 30 November 2016 
Certolizumab pegol in Crohn's disease
 30 November 2016 
Genetic risk of Crohn's in chronic granulomatous disease
 30 November 2016 
Rifaximin in diarrhea-predominant IBS
 29 November 2016 
Assessing liver steatosis
 29 November 2016 
Treating Zenker's diverticulum
 29 November 2016 
Colorectal cancer surveillance in ulcerative colitis
 28 November 2016 
Complications in celiac disease
 28 November 2016 
Monitoring IBD with mobile technology
 28 November 2016 
Reducing warfarin-related upper GI bleeds
 25 November 2016 
Metal vs plastic stents for pancreatic cancer surgery
 25 November 2016 
Yoga and IBS therapy 
 25 November 2016 
Colorectal cancer screening issues
 24 November 2016 
Partner burden in celiac disease
 24 November 2016 
Fusobacterium nucleatum for colorectal cancer prognosis
 24 November 2016 
PPIS and gastric cancer risk
 23 November 2016 
Diagnosing autoimmune pancreatitis
 23 November 2016 
Readmissions in cirrhosis
 23 November 2016 
Quality assurance standards for colonoscopy
 22 November 2016 
Fatigue in IBD
 22 November 2016 
PPIs and C. diff in ICU 
 22 November 2016 
Bile acid diarrhea in function bowel disorder with diarrhea
 21 November 2016 
Financial incentives and colorectal cancer screening
 21 November 2016 
Pain after endoscopic resection of gastric tumors
 21 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 18 November 2016 
Colorectal cancer risk and self-reported family history
 18 November 2016 
Ustekinumab in Crohn’s disease
 18 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 17 November 2016 
Risk of overweight in infants
 17 November 2016 
Moderate alcohol consumption and NAFLD
 17 November 2016 
Liver-related specialty care in patients with Hep C
 16 November 2016 
PPI therapy in liver disease
 16 November 2016 
Education in Gastroenterology fellowship
 16 November 2016 
Paternal preconceptional use of anti-TNF-α agents
 15 November 2016 
Novel treatment of NASH 
 15 November 2016 
Physician perspectives on Hep C management
 15 November 2016 
Contraceptives and ulcerative colitis
 14 November 2016 
Cardiovascular risk in NAFLD 
 14 November 2016 
Vit D and NAFLD
 14 November 2016 
Malignancy risk in IBD 
 11 November 2016 
Treatment of Hep C along with opioid agonist therapy
 11 November 2016 
Diabetes and liver cancer risk in Hep C cirrhosis
 11 November 2016 
Biomarker of cirrhosis progression
 10 November 2016 
Testosterone levels and cirrhosis outcomes in men
 10 November 2016 
Improving bowel quality before colonoscopy
 10 November 2016 
Fecal microbiota transplantation and CDI episodes
 09 November 2016 
Minimizing costs of esophagogastroduodenoscopy and colonoscopy
 09 November 2016 
Risk of TB in IBD patients receiving therapy
 09 November 2016 
Liver transplant wait-list and mortality in infants

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us